Literature DB >> 8923307

Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome.

C C Huang, C C Chu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923307     DOI: 10.1007/bf00873980

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  3 in total

1.  Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome.

Authors:  T Henze; G Krieger
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

Review 2.  Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

Authors:  J M Leger; A B Younes-Chennoufi; B Chassande; G Davila; P Bouche; N Baumann; P Brunet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 3.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

  3 in total
  3 in total

Review 1.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 2.  An update on the diagnosis and management of the polyneuropathy of POEMS syndrome.

Authors:  Federica Cerri; Yuri Matteo Falzone; Nilo Riva; Angelo Quattrini
Journal:  J Neurol       Date:  2018-09-27       Impact factor: 4.849

3.  Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.

Authors:  Qiang Li; Fang Xu; Jing-Feng Duan; Yu-Feng Tang
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.